A Study of two investigational drugs including PVX-410 (a Multi-Peptide Cancer Vaccine), and Citarinostat (a Histone Deacetylase Inhibitor (HDAC)) +/- Lenalidomide for Patients with Moderate or High Risk of Progression Smoldering Multiple Myeloma

Trial Overview

Am I Eligible?

Participating US Centers

Massachusetts General Hospital

This center is currently accepting patients.

Boston, MA

University Hospitals
Seidman Cancer Center at UH Case Medical

This center is currently accepting patients.

Cleveland, OH


This trial is currently open and accepting patients.

Additional Information
Trial Phase

Phase 1

Trial Enrollment

20 sparks required

Trial Sponsors
  • Massachusetts General Hospital
Trial Collaborators
  • Celgene Corporation
  • OncoPep, Inc.
Trial Identifiers

Need Help?

(888) 828-2206

Weekdays 9am - 5pm EST